Since full-length RUNX1 is known to generally activate T cell differentiation genes and suppress multipotent hematopoietic genes [33], expression of these newly predicted dominant negative isoforms is consistent with supporting leukemogenic potential in Jurkat T-ALL. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.